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bisdemethoxycurcumin) were determined at baseline and 
at various intervals after oral administration over a 12-h 
period.
Results CW8 showed the highest plasma concentrations 
of curcumin, demethoxycurcumin, and total curcuminoids, 
whereas CSL administration resulted in the highest levels 
of bisdemethoxycurcumin. CW8 (39-fold) showed signifi-
cantly increased relative bioavailability of total curcumi-
noids  (AUC0−12) in comparison with the unformulated 
StdC.
Conclusion The data presented suggest that 
γ-cyclodextrin curcumin formulation (CW8) signifi-
cantly improves the absorption of curcuminoids in healthy 
humans.
Keywords Curcumin · Cyclodextrin · Bioavailability · 
Humans · Plasma pharmacokinetics
Introduction
Curcuma longa L. (Zingiberaceae), known as turmeric, 
has been used in the traditional medicine in China and 
India for centuries. Turmeric consists of natural bioactive 
hydrophobic polyphenols called curcuminoids of which 
curcumin is the main component derived from the rhizome 
of the herb. With its extensive pharmacological activities, 
including antioxidant, anti-cancer, antimicrobial, anti-
inflammatory, and anti-diabetic properties [1–3], a variety 
of studies have investigated the mode of action of curcumin 
in signal transduction pathways linked to inflammation. For 
example, curcumin has been shown to inhibit IL-6-induced 
STAT3 phosphorylation and consequent STAT3 nuclear 
translocation in multiple types of myeloma cell lines [4]. 
In addition, cell culture studies have shown that curcumin 
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Purpose The optimal health benefits of curcumin are lim-
ited by its low solubility in water and corresponding poor 
intestinal absorption. Cyclodextrins (CD) can form inclu-
sion complexes on a molecular basis with lipophilic com-
pounds, thereby improving aqueous solubility, dispers-
ibility, and absorption. In this study, we investigated the 
bioavailability of a new γ-cyclodextrin curcumin formula-
tion (CW8). This formulation was compared to a standard-
ized unformulated curcumin extract (StdC) and two com-
mercially available formulations with purported increased 
bioavailability: a curcumin phytosome formulation (CSL) 
and a formulation of curcumin with essential oils of tur-
meric extracted from the rhizome (CEO).
Methods Twelve healthy human volunteers participated 
in a double-blinded, cross-over study. The plasma con-
centrations of the individual curcuminoids that are present 
in turmeric (namely curcumin, demethoxycurcumin, and 
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prevents TNF-α-induced IL-1 and IL-6 production by inter-
fering with the nuclear factor kappa-light-chain enhancer 
of activated B cells (NF-κB) and mitogen-activated pro-
tein kinases (MAPK) pathways [5–7]. In microglia and 
macrophage cell lines, curcumin also has shown to have 
an inhibitory effect on cyclooxygenase-2 (COX-2) and 
inducible nitric oxide synthase (iNOS) expression, leading 
to decreased levels of prostaglandin  E2 (PGE2) and nitric 
oxide (NO) [7–9]. Furthermore, curcumin decreases TNF-
α, IL-1, -2, -8, and -12 production in phorbol myristate 
acetate (PMA) or lipopolysaccharide (LPS) stimulated 
monocytes and alveolar macrophages in a concentration- 
and time-dependent manner, depicting its broad cytokine-
suppressive anti-inflammatory action [10].
While early human clinical trials showed beneficial 
effects for cancer [11, 12], arthritis [13], immune deficien-
cies [14], and cardiovascular health [15], its potential seems 
to be limited by poor absorption [16]. Curcumin is prac-
tically insoluble in water resulting in insufficient absorp-
tion from the gut, and pharmacokinetic studies showed a 
fast metabolism and quick systemic elimination [17]. The 
maximal total curcumin plasma concentration in humans 
reported in the literature was 3228.0 ± 1408.2 ng/ml when 
410  mg curcumin was given as liquid micelles [18]. The 
majority of orally ingested curcumin is excreted through 
the faeces in a non-metabolised form [19]. Absorbed cur-
cumin and its metabolites are rapidly converted into water-
soluble metabolites, glucuronides, and sulfates [20, 21]. 
Through an NADPH-dependent mechanism and reduction, 
curcumin is converted into dihydrocurcumin and tetrahy-
drocurcumin (Fig. 1) [22, 23].
The gut microbiota plays an important role in curcumin 
metabolimn and biotranformation, as the microbiota is 
capable of transforming curcumin formulations which 
contain approximately 77% curcumin, 17% demethoxy-
curcumin, and 6% bisdemethoxycurcumin (Fig.  2) into a 
range of catabolites [16]. For example, Tan et  al. investi-
gated the colonic metabolism of three curcuminoids [80.1% 
curcumin, 15.6%, demethoxycurcumin (DMC), and 2.6% 
bisdemethoxycurcumin (Bis-DMC)] in an in  vitro model 
containing human faecal starters. Up to 24% of curcumin, 
61% of demethoxycurcumin (DMC), and 87% of bisdem-
ethoxycurcumin (Bis-DMC) were degraded by the human 
faecal microbiota after 24  h of fermentation in  vitro. 
Three main metabolites, namely, tetrahydrocurcumin 
(THC), dihydroferulic acid (DFA), and 1-(4-Hydroxy-3-
methoxyphenyl)-2-propanol, were detected in the fermenta-
tion cultures [24].
Cyclodextrins have been widely used in pharmaceuti-
cal and nutritional formulations to form an inclusion com-
plex on a molecular basis with lipophilic compounds for 
the improvement of their aqueous dispersibility and cor-
responding bioavailability [25]. α-, β-, and γ-Cyclodextrin 
are a family of cyclic oligosaccharides consisting of non-
reducing chiral glucose building blocks linked into a ring. 
The corresponding structure of the hydrophilic glucose 
building blocks face outwards and results in a lipophilic 
cavity on the inside (Fig. 3). The size and shape of the cav-
ity allow a lipophilic molecule to reside as a “guest”. The 
cohesion between the cyclodextrin and the guest molecules 
is produced by relatively weak van der Waals forces, so 
that the guest molecule can be liberated again under suit-
able conditions. The weak van der Waals forces in such 
inclusion complexes leave the two counterpart molecules 
unchanged and in equilibrium. About 30 different pharma-
ceutical products containing cyclodextrins are now on the 
market worldwide, and numerous food products, cosmetics, 
and other commercial products contain cyclodextrins. In 
these products, cyclodextrins are mainly used solubilizing 
agents to increase water solubility of lipophilic compounds 
[26].
In contrast to α- and β-cyclodextrin, γ-cyclodextrin is 
completely digested by salivary and pancreatic amylase. In 
animals, the administration of tocotrienol-γ-cyclodextrin 
complex resulted in higher plasma and tissue tocotrienol 
concentrations by enhancing intestinal absorption [27]. 
After a single dose of a capsule containing the inclu-
sion complex of coenzyme Q10 with γ-cyclodextrin, the 
coenzyme Q10 plasma levels were significantly elevated 
[28]. These findings suggest that the complexation of 
lipophilic curcumin with γ-cyclodextrin may improve its 
bioavailability.
Therefore, the purpose of this study was to evaluate 
the plasma levels of curcuminoids (curcumin, demethoxy-
curcumin, and bisdemethoxycurcumin) of an acute oral 
administration of a novel curcumin-γ-cyclodextrin complex 
containing curcumin (CW8) in comparison with standard 
unformulated curcumin (StdC). In addition, a curcumin 
phytosome formulation consisting of Curcumin: Soy Leci-
thin: Microcrystalline Cellulose in a ratio of 1:2:2 (CSL) 
and a formulation consisting of curcuminoids and essential 
Fig. 1  Chemical structures of the curcuminoids. The main curcumi-
noids isolated from the curcuma longa rhizome are curcumin, dem-
ethoxycurcumin (one O–CH3 group replaced by H), and bisdemetox-
ycurcumin (two O–CH3 groups replaced by H)
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Fig. 2  Metabolic pathway of orally ingested curcumin. Curcumin 
and its reduced metabolites dihydrocurcumin and tetrahydrocurcumin 
are conjugated with glucuronide and/or sulfate, resulting in curcumin 
glucuronoside, dihydocurcumin glucuronoside, tetrahydrocurcumin 
glucuronoside, or corresponding monosulfate and mixed sulfate/glu-
curonosides
Fig. 3  Structure of cyclodextrins. Cyclodextrins are cyclic oligosac-
charides consisting of (α-1,4)-linked α-D-glucopyranose units. The 
corresponding structure of the hydrophilic glucose building blocks 
face outwards and results in a lipophilic cavity on the inside. The 
size and shape of the cavity allow a lipophilic molecule to reside as 
a “guest”. The cohesion between the cyclodextrin and the guest mol-
ecules is produced by relatively weak van der Waals forces, so that 
the guest molecule can be liberated again under suitable conditions
 Eur J Nutr
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Out of 15 subjects recruited for this study, 12 subjects com-
pleted the study (11 male, 1 female; age 23.0 ± 2.4 years; 
height 182.9 ± 6.1  cm; weight 86.2 ± 4.2  kg, 1 African 
American and 11 Caucasians). One volunteer did not start 
the study and another volunteer dropped out of the study 
due to personal reasons. During blood withdrawal, another 
volunteer was feeling faint and, therefore, was advised 
not to proceed with the study. Volunteers participating in 
the study needed to meet the following inclusion param-
eters: 20–35 years of age have not been consuming any 
curcumin-containing supplements (curcumin, turmeric, 
and curry) or foods (curcumin, turmeric, and curry for 2 
weeks prior to testing; no history of any of the following: 
hyperacidity, gastric/duodenal ulcers, gastrointestinal prob-
lems, and gallbladder problems; no use of any blood thin-
ners/anti-thrombotic agents or NSAIDs; no prior use of 
blood sugar-lowering agents, H2 blockers, or proton pump 
inhibitors; non-hyperglycaemic, non-haemophiliac, and 
non-diabetic; and no known allergies to soy. The University 
of Tampa Institutional Review Board approved the proto-
col (IRB, 07/02/2013, Ref: 13-07). Before each testing, all 
subjects underwent screening and signed informed written 
consent to guarantee eligibility and voluntary willingness 
to take part.
Study materials
Product names have been omitted due to the absence of 
consent for disclosure. The total mass of each of the prepa-
rations was matched by using inert filler material (micro-
crystalline cellulose). All volunteers were supplemented 
with visually identical six hard gel capsules of each of the 
study materials per setting, resulting in either 376  mg of 
total curcuminoids for CW8, CSL and CEO and 1,800 mg 
of total curcuminoids for StdC in accordance with the study 
dosage established by the Cuomo et  al. [19]. Prior to the 
study, capsules of each product were analysed and the 
actual amount of the curcuminoids per serving was calcu-
lated as mean values (Table 1).
Study procedure
All 12 subjects completed the four separate trials of the 
four formulations, with nine blood samples drawn from 
each in 1 day, in a randomized, double-blinded order 
separated by a 7-day wash-out period between each formu-
lation. The curcumin formulations were blinded through a 
special code, so that the investigators, as well as the volun-
teers, did not know which formulation was consumed dur-
ing each session.
Before each trial, the subject reported to the laboratory 
in the morning following a 10-h overnight fast (except for 
water). Blood was drawn by introducing a catheter into the 
forearm vein by a qualified phlebotomist. First, the baseline 
blood sample was obtained, followed by one of four treat-
ments with the defined four curcumin preparations which 
were consumed with water. Further blood samples were 
then drawn at the timepoints of 1, 2, 3, 4, 5, 6, 8, and 12 h 
following product supplementation (Fig.  4). These time-
points were selected as past studies have shown that the 
majority of digestion and absorption are practically com-
plete within this timeframe. Each time after the 4- and 8-h 
blood sample draw, a curcumin-free standardized meal was 
delivered. During the first mealtime, 40 g chocolate whey 
protein isolate and 80  g instant oatmeal dissolved in 30 
mL of water plus 473 mL of water to drink were served. 
During the second mealtime, 230 g turkey breast, 2 slices 
of whole wheat bread, 15  g light miracle whip, 170  g of 
fat free Greek yogurt, and 473 mL of water to drink were 
served. All subjects remained in the laboratory the entire 
experiment to ensure full compliance. .
Sample collection
At each blood withdrawal timepoint, 6 mL of blood were 
drawn off the catheter into vacutainer tubes, followed by 
centrifugation of the blood tubes at 2000×g for 10 min and 
the plasma was aliquoted into Eppendorf tubes for storage 
until analysis. To avoid degradation during the storage, the 
blood plasma samples were stored in a −80 °C freezer until 
analysis.
Sample preparation
The plasma samples were prepared according to Cuomo 
et al. [29]. A 0.2 mL aliquot of plasma was transferred to 
a clean microcentrifuge tube and spiked with 100 μL of a 
Table 1  Analytical results of study materials
StdC (mg) CSL (mg) CEO (mg) CW8 (mg)
Curcumin 1774.2 354.0 355.2 348.0
Demethoxycur-
cumin
162.0 26.4 35.4 21.6
Bisdemethoxycur-
cumin
9.0 1.2 1.8 2.4
Total Curcumioids 1945.2 382.2 392.4 371.4
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solution containing 1000 U of β-glucuronidase/sulfatase 
(EC 3.2.1.31) from Helix pomatia (Sigma, St. Louis, MO) 
in 0.1 M phosphate buffer (pH 6.86) and 50 μL of methanol 
to liberate free curcumin [30], as a substantial amount of 
curcumin is glucuronidated or sulfated [23]. For enzymatic 
hydrolysation of the phase-2 conjugates of curcuminoids, 
the resultant mixture was thoroughly vortexed and incu-
bated at 37 °C for 1 h. In a subsequent incubation, curcumi-
noids were extracted with 1 mL of ethyl acetate, and the 
mixture was then vortexed for 1 min, followed by sonica-
tion in a water bath for 15 min. After 6 min of centrifuga-
tion at 15,000g, the resulting upper organic layer was trans-
ferred to a 2 mL microcentrifuge tube and evaporated at 
30 °C under negative pressure in a centrifugal concentrator 
to remove residual solvent. This extraction procedure was 
repeated for a total of two extractions. After treating the 
dried extract with 100 μL of methanol, 10 μL were injected 
into the HPLC-MS/MS. “Salbutamol” (ISTD) was used as 
an internal standard to ensure data accuracy. All standard 
curcuminoids for the quantification were purchased from 
Sigma Aldrich, USA.
Chromatographic analysis of the curcuminoids
Blood plasma samples were analysed by tandem mass spec-
trometry detection (HPLC/MS/MS) to determine curcumin, 
demethoxycurcumin, and bisdemethoxycurcumin levels as 
published previously [29, 31, 32]. Briefly, the HPLC-MS-
MS consisted of an Agilent 1290 HPLC system with an 
Agilent 6460 tandem mass spectrometer with ESI source in 
positive mode. Chromatographic separation was achieved 
by a Kinetex XB-C18 100  Å column (2.1 × 50  mm, 2.6 
micron) attached to a security guard ultra, C18, 2.1  mm 
pre-column. The column chamber temperature was set to 
50 °C. The mass spectrometer was run in the multiple reac-
tion monitoring (MRM) mode, and the transitions moni-
tored were m/z 369.1 → 285.1 for curcumin, 339.1 → 
255.1 for demethoxycurcumin, and 309.1 → 225.0 for bis-
demethoxycurcumin. Concentrated stock solutions of cur-
cumin, demethoxycurcumin, and bisdemethoxycurcumin 
were prepared by dissolving 5.0 mg of each compound in 
200 mL of methanol to give 25 μg/mL stock solutions. Cal-
ibration standards were prepared daily by spiking 1 mL of 
blank plasma with the appropriate working solution result-
ing in concentrations of 0.5, 50, 100, 200, and 500 ng of 
curcumin, its derivaties and salbutamol per ml plasma as 
described previously [32]. A six-point calibration curve 
was created by plotting the peak area ratio (y) of curcumin 
to the internal standard salbutamol vs. the curcumin con-
centration. The calibration curves were linear in human 
plasma with curves (r = .99) for curcumin. Similar results 
were obtained for demethoxycurcumin and bisdemethoxy-
curcumin. The analysis was carried out in a water/methanol 
gradient, and the flow rate was 0.25 mL/min and the mobile 
phase was mixed from two components: A—water contain-
ing 0.1% formic acid; B—methanol containing 0.1% for-
mic acid. Gradient conditions were: 70% B at 0 and 3 min, 
increasing to 98% B at 5 and 6 min, before returning back 
to 70% B at 7.5 min. Salbutamol (50 µg/mL) was used as 
an internal standard as described previously [32]. Blank 
human serum was pooled together and stored at −20 °C 
prior to use for the preparation of calibration standards and 
quality control samples.
Pharmacokinetic analysis
Pharmacokinetic data following the oral administration of 
the curcumin formulations were calculated by Graphpad 
Prism 5 and PKSolver using non-compartmental analysis 
[33].  Cmax was the maximum observed plasma concentra-
tion directly from the mean plasma concentration time pro-
file (median are also presented in and the area under the 
plasma concentration time curve (AUC) was calculated 
by the definite integral from 0 to 12 h of the mean plasma 
Fig. 4  Schematic representation of the study protocol. Each vol-
unteer reported to the laboratory in the morning between 6:00 and 
10:00 h following a 10-h overnight fast (except for water). A catheter 
was introduced into a forearm vein by a qualified phlebotomist. After 
equilibration, a baseline blood sample (pre) was collected and one of 
four treatment dosages of curcumin was consumed with water. Blood 
samples were then drawn at 1, 2, 3, 4, 5, 6, 8, and 12-h intervals fol-
lowing product consumption. After the 4- and 8-h blood samples had 
been drawn, a turmeric-free standardized meal was provided
 Eur J Nutr
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concentration time curves using the additive method. StdC 
was given to the participants at approximately five times the 
dose; therefore, normalized values for StdC (where normal-
ized C and  AUC0−12 values were divided by the content of 
each curcuminoid for each preparation divided by the cur-
cumin content of the larger dose of StdC) are also presented 
in Table 1 and used for the statistical comparisons. Calcula-
tion of t½ could not take place for all curcumin preparations 
as a number of the formulations did not decline in concen-
tration over the 12-h time period. Both programs yielded 
identical values for  AUC0−12 and  Cmax (additive method).
Statistical analysis
The data were expressed as mean ± SEM and pharma-
cokinetics analysis performed using Pk solver and Graph-
pad Prism 5 (Fig. 5). A second analysis is also presented 
(Table  2) using the median (IQR), as the outcome was 
non-normal in each occasion and Friedman’s test was 
performed to examine whether the outcome varied sig-
nificantly by the four types of curcumin formulations 
examined in this study. For the median, Friedman’s test 
is a type of non-parametric-repeated-measures one-way 
ANOVA. If it was significant, the parameters were com-
pared in pairs by the non-parametric sign test adjusted 
for multiple comparisons using the Bonferroni method. 
Signed rank test or paired t test was not performed as 
the outcome for each comparison was neither symmetri-
cal nor normal Out of the six all possible comparisons 
between any two types of curcumin concentrations, the 
comparison between CEO and CSL was not of interest. 
This produced five comparisons—between StdC and 
CW8, CEO, and CSL and between CW8 and CEO, CSL. 
In total, four-repeated-measures non-parametric ANOVA 
models were fitted for Cmax (one each for curcumin, 
demethoxycurcumin, bisdemethoxycurcumin, and total 
curcuminoids). Similarly, four-repeated-measures non-
parametric ANOVA models were fitted for AUC. The 
Curcumin














































































































Fig. 5  Plasma concentration time curves for curcumin, demeth-
oxycurcumin, bisdemethoxycurcumin, and total curcuminoids for 
the four different curcumin formulations. Pharmacokinetic data of 
the individual and combined total curcuminoids for the four formu-
lations were each plotted on a plasma concentration vs. time curve. 
From these data, the area under the plasma concentration time 
curve (AUC), Cmax, tmax, and relative absorption was calculated for 
each curcuminoid and the combined curcuminoids. Concentrations 
(means ± SEM) are expressed in ng/mL and refer to enzymatically 
hydrolyzed plasma samples
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adjusted p values of less than 0.05 were considered statis-
tically significant for each pairwise comparison.
Results
To improve the bioavailability of curcumin, many differ-
ent approaches, including the design and development of 
nanoparticles, self-assemblies, nanogels, liposomes, and 
complex fabrication, have been developed for sustained and 
efficient curcumin delivery [32].
In our study, we have compared four different commer-
cially available curcumin formulations and analysed their 
pharmacokinetic profile in 12 subjects in a randomized, 
double-blind, cross-over study over a 12-h time period.
The subjects consumed either 376 mg of total curcumi-
noids in the form of CW8, CEO, and CSL or 1,800 mg of 
the corresponding non-formulated StdC. All four treat-
ments were well tolerated, and no adverse events were 
reported.
Curcumin, demethoxycurcumin, and bisdemethoxy-
curcumin plasma levels were measured by HPLC-MS/MS 
analysis after Helix pomatia glucuronidase/sulfatase treat-
ment to liberate the parent compounds from sulfate and 
glucoronidate conjugates.
For each formulation, the pharmacokinetic data of the 
individual curcuminoids were plotted on a plasma concen-
tration vs. time curve (Fig. 5). The area under the plasma 
concentration time curve (AUC), Cmax, tmax, and relative 
bioavailability (F) were calculated for each curcuminoid in 
the four formulations (Table 2). The relative bioavailability 
was calculated by dividing the measured value of test prod-
uct (CSL, CEO, or CW8) by the measured value of refer-
ence product (StdC) multiplied by the dosage of the refer-
ence product divided by dosage of the test product.
CW8 showed the highest mean plasma concentra-
tions of curcumin and total curcuminoids (73.2 ± 17.5 and 
87.0 ± 20.5  ng/mL, respectively), whereas CSL adminis-
tration resulted in the highest mean plasma levels of bis-
demethoxycurcumin (1.9 ± 0.3  ng/mL). For demethoxy-
curcumin, CW8 and CSL yielded the highest mean plasma 
Table 2  Pharmacokinetic parameters of curcuminoid concentrations: area under the plasma concentration time-curve  (AUC0–12h), Cmax, and 
relative absorption for each treatment
Data are expressed as mean ± standard errors of the mean or as median (IQR). Significances were calculated based on the medians. P values less 
than 0.05 (a), 0.01 (b) and 0.001 (c) were considered statistically significant (based on pairwise comparisons using signed test with Bonferroni 
adjustments) in comparison to the Normalized StdC values. P values less than 0.05 (d), 0.01 (e) and 0.001 (f) were considered statistically signif-
icant (based on pairwise comparisons using signed test with Bonferroni adjustments) in comparison to CW8 values (note that the dose of StdC 
was approximately 5x that of the three other curcumin formulations, and therefore a normalized value was used for the statistical comparisons)
Curcuminoid Formulation AUC0-12 (ng/
mL h) (means ± 
SEM)
Cmax (ng/







tmax (h) Relative 
absorption 
(fold)
Curcumin StdC (5x dose) 19.7 ± 2.6 2.3 ± 0.4 19.7 (2.6) 0.3 (0.3) 12 1.0
StdC (normalized) 3.9 ± 0.5 0.5 ± 0.1 3.5 (2.2) 0.0f (0.5) 12 1.0
CEO 6.7 ± 0.5 0.9 ± 0.3 5.8f (2.2) 5.2c (18.9) 6 1.7
CSL 35.1 ± 4.5 4.7 ± 1.8 34.2f (25.1) 10.4c (13.6) 1 9.0
CW8 327.7 ± 58.1 73.2 ± 17.5 293.4c (205.8) 1.2 (0.4) 1 85.0c
Demethoxy-curcumin StdC (5x dose) 21.8 ± 3.1 2.2 ± 0.4 21.8 (3.1) 0.1 (0.2) 4 1.0
StdC (normalized) 3.8 ± 0.5 0.4 ± 0.1 3.7 (2.9) 0.3e (0.5) 4 1.0
CEO 2.5 ± 0.8 0.3 ± 0.1 1.3f (5.5) 2.0c (2.3) 6 0.5
CSL 41.8 ± 7.5 5.0 ± 0.7 37.2c (25.4) 1.1c (1.8) 6 11.9c
CW8 51.5 ± 9.0 12.4 ± 2.7 43.6c (43.1) 4.7 (0.8) 1 17.9c
Bisdemethoxy-curcumin StdC (5x dose) 10.6 ± 1.4 1.2 ± 0.4 10.6 (1.4) 0.8 (0.7) 1 1.0
StdC (normalized) 2.1 ± 0.3 0.2 ± 0.1 2.0 (1.8) 1.0f (0.4) 1 1.0
CEO 2.9 ± 0.8 0.3 ± 0.1 3.4d (5.8) 8.1c,f (27.3) n/a 1.4
CSL 10.0 ± 1.0 1.9 ± 0.3 9.4a (4.4) 67.8c (93.2) 2 7.1c
CW8 9.4 ± 1.3 1.4 ± 0.3 8.0c (4.6) 0.3 (0.3) 1 3.3c
Total curcuminoids StdC (5x dose) 52.1 ± 6.4 4.7 ± 0.8 52.1 (6.4) 0.0f (0.5) 4 1.0
StdC (normalized) 10.4 ± 1.3 0.9 ± 0.1 10.6 (6.5) 5.2c (18.9) 4 1.0
CEO 12.1 ± 1.4 1.1 ± 0.1 11.4f (6.8) 10.4c (13.6) 4 1.1
CSL 86.9 ± 12.1 18.0 ± 6.4 88.1f (45.9) 1.2 (0.4) 1 8.5
CW8 388.6 ± 66.8 87.0 ± 20.5 343.7c (293.9) 0.1 (0.2) 1 39.1c
 Eur J Nutr
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concentrations (12.4 ± 2.7 and 5.0 ± 0.7  ng/mL, respec-
tively). CW8 and CSL reached  Cmax at 1 h after adminis-
tration, whereas the other formulations showed a delayed 
uptake (Fig. 5; Table 2).
Discussion
While most of the formulations are targeting drug deliv-
ery, only a few food-grade preparations have been stud-
ied [29, 34, 35]. Many different strategies to increase the 
potential bioavailability of curcumin have been explored in 
the recent past, including the design and development of 
nanoparticles, self-assemblies, nanogels, liposomes, and 
micelles, have been developed for sustained and efficient 
curcumin delivery [36].
One approach to increase curcumin absorption involves 
more components of the raw turmeric root to be included in 
the preparation. For example, the combination of curcumi-
noids and essential oils of turmeric rhizome (CEO) have 
been shown to increase the absorption of curcumin by 6.9-
fold [34]. The inclusion of curcumin in a lipophilic matrix 
(Phytosomes, Curcumin:Soy Lecithin:Microcrystalline 
Cellulose 1:2:2, CSL) has been shown to increase the rela-
tive human bioavailability of curcumin by 19.2-fold for 
curcumin alone [29]. A formulation of curcumin with a 
combination of hydrophilic carrier, cellulosic derivatives, 
and natural antioxidants (Curcuwin, OmniActive) has aslo 
be shown to significantly increased curcuminoid bioavail-
ability compared to unformulated standard curcumin [31].
In this study, four different curcumin preparations were 
tested side by side with in the same human subjects. CW8 
showed the highest plasma concentrations of curcumin, 
demethoxycurcumin, and total curcuminoids, whereas CSL 
administration resulted in the highest levels of bisdem-
ethoxycurcumin. CW8 (39.1-fold) showed significantly 
increased relative bioavailability of total curcuminoids 
 (AUC0−12) in comparison with unformulated StdC.
Cuomo et al. showed that the lecithin in CSL increased 
the uptake of the demethoxylated forms of curcumin into 
the blood plasma [29]. In the standard curcumin formula-
tions, the curcumin content is four times higher than the 
amount of demethoxycurcumin; nevertheless, the formu-
lation with lecithin (CSL) results in demethoxycurcumin 
being the major plasma curcuminoid, and not curcumin. 
This was emulated in our study for CSL, whereas curcumin 
was the major plasma curcuminoid for CW8.
However, the pharmacokinetic parameters for CSL 
cannot be compared to those in the study by Cuomo 
et al. as both studies show significant differences in study 
design [29]. The first major difference was the duration of 
blood sampling. Cuomo et al. drew blood samples over a 
24-h period of time, compared to 12 h in this study. The 
second difference was the nutritional status. The subjects 
in this study were fasted, while Cuomo et al. gave a high 
fat meal with the curcumin supplementation which has 
shown to slow the mean transit time (MTT) in the gastro-
intestinal tract and, therefore, improve the absorption of 
fat soluble ingredients. Regarding the analytical method, 
Cuomo et al. did not use an internal standard. Therefore, 
in this study, an internal standard, “Salbutamol” (ISTD), 
was used to improve accuracy and reliability of the data 
outcome as previously described by Lao et al. 2006 in an 
absorption study in rats [37]. Due to the differences in 
design, absolute values between the two studies cannot be 
compared.
Another curcumin absorption study conducted by 
Antony et al. showed the effects of a formulation of cur-
cumin with essential oils of turmeric extracted from the 
rhizome (CEO) and a curcumin–lecithin–piperine over 
a curcumin control in 11 healthy volunteers in a cross-
over design with a 3-week wash-out period [34]. For the 
analytical method, an internal standard was not applied, 
resulting in determination of curcumin alone in the blood 
for up to 8 h after administration. As a result, the formu-
lation showed a 6.9-fold increased absorption over con-
trol, whereas in this study, a much lower increase with 
approximately 30% relative absorption of CEO was 
demonstrated.
In a dose escalation study conducted by Lao et al., the 
safety and appearance of curcumin were determined in the 
blood of a single dose of StdC, the same material used as 
the control in this study [37]. Twenty-four healthy subjects 
(n = 24) consumed increasing single doses of 500, 1000, 
2000, 4000, 6000, 8000, 10,000, and 12,000 mg of StdC. 
Surprisingly, no curcumin was detected in serum at up to 
8 g of StdC. Only at a dose level of 10,000 and 12,000 mg 
in two volunteers resulted in low levels of curcumin, 
whereas no curcumin could be detected in the remaining 
subjects at the 10,000- or 12,000-mg dose levels [37]. A 
further highly bioavailable curcumin preparation is Long-
vida, a patented technology using Solid Lipid Curcumin 
Particle (SLCP™) Technology [38]. Novasol curcumin is 
incorporated into biomimetic micelle with a diameter of 
approximately 30 nm with purported bitter bioavailability 
as liposomal preparations [18].
The absolute values of other studies cannot be compared 
with the results of this study due to variances in subjects, 
analytical method, study design, and administration of the 
product.
This present study is one of the few studies in which four 
different curcumin preparations were compared in the same 
cohort of subjects, and where the different curcuminoids 
in the curcumin formulation (curcumin, bisdemethoxycur-
cumin, and demethoxycurcumin) were analysed and com-
pared, aided by the use of an internal standard.
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